Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209–3216.
   PubMed Web of Science ®Google Scholar
• Robak T. New horizons in the treatment of chronic lymphocytic leukemia. Acta Haematol Pol 2014;45:122–131.
   Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370: 997–1007.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369: 32–42.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 2014;124: 2196–2202.
   PubMed Web of Science ®Google Scholar
• Pleyer L, Egle A, Hartmann N, et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405–418.
   PubMed Web of Science ®Google Scholar
• Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002;2:945–956.
   PubMed Web of Science ®Google Scholar
• Fuentes-Panana EM, Bannish G, Monroe JG. Basal B-cell receptor signaling in B lymphocytes: mechanisms of regulation and role in positive selection, differentiation, and peripheral survival. Immunol Rev 2003;21:841–894.
   Web of Science ®Google Scholar
• Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia. Revelations from the B-cell receptor. Blood 2004;103:4389–4395.
   PubMed Web of Science ®Google Scholar
• Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251–262.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt LM. Aggressive lymphomas. N Eng J Med 2010;362:1417–1429.
   PubMed Web of Science ®Google Scholar
• Avalos AM, Meyer-Wentrup F, Ploegh HL. B-cell receptor signaling in lymphoid malignancies and autoimmunity. Adv Immunol 2014;123:1–49.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287–6296.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2014;28:649–657.
   PubMed Web of Science ®Google Scholar
• Chang BY, Francesco M, De Rooij MF, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013;122:2412–2424.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31: 88–94.
   PubMed Web of Science ®Google Scholar
• Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015;29:783–787.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015;125:2497–2506.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286–2294.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48–58.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015;16:169–176.
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib in combination with rituximab is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia: new, updated results of a phase II trial in 40 patients. Blood (ASH Annual Meeting Abstracts) 2013;122:675.
   Web of Science ®Google Scholar
• Brown JR, Barrientos JC, Barr PM, et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/ refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results of a phase 1b study. Blood 2013;122 (Suppl):525 (Abstr).
   Google Scholar
• Brown JR, Barrientos JC, Barr PM, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 2015;125:2915–2922.
   PubMed Web of Science ®Google Scholar
• Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015;125:2062–2067.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317–330.
   PubMed Web of Science ®Google Scholar
• Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009;139:573–586.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078–2088.
   PubMed Web of Science ®Google Scholar
• Barragan M, Bellosillo B, Campas C, et al. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 2002;99:2969–2976.
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002;100:3741–3748.
   PubMed Web of Science ®Google Scholar
• Brown R, Furman RR, Flinn I, et al. Final results of a phase I study of idelalisib (GSE 1101) a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory CLL. J Clin Oncol (ASCO Annual Meeting Abstracts) 2013;31:7003.
   Web of Science ®Google Scholar
• Barrientos JC, Furmann RR, Leonard J, et al. Update on a phase I study of the selective PI3K {delta} inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol 2013;31 (Suppl):7017 (Abstr).
   Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603–3612.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820–2822.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes. Blood 2012;119:5348.
   Web of Science ®Google Scholar
• Barrientos JC, Furman RR, Leonard J, et al. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS- 1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol (ASCO Annual Meeting Abstracts) 2013;31:7017.
   Web of Science ®Google Scholar
• Wagner-Johnston ND, de Vos S, Coutre SE, et al. Chemoimmunotherapy combination of idelalisib with bendamustine/rituximab or chlorambucil/rituximab in patients with relapsed/refractory CLL demonstrates efficacy and tolerability. Blood (ASH Annual Meeting Abstracts) 2013;122:4176.
   Google Scholar
• de Vos S, Furman RR, Barrientos JC, et al. Idelalisib, a selective inhibitor of PI3Kδ, in combination with bendamustine, fludarabine or chlorambucil in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2013;122:2878.
   Web of Science ®Google Scholar
• Coutre S, Leonard J, Furman R, et al. Update on a phase 1 study of the selective PI3K-delta inhibitor, idelalisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia. Haematologica 2013;98 (Suppl):(Abstr S1150).
   Google Scholar
• de Vos S, Leonard JP, Barrientos JC, et al. A phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2013;122:4180.
   Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kd) inhibitor idelalisib (GS-1101) in combination with rituximab in treatment-naive patients > 65 years with chronic lymphocytic leukemia or small lymphocytic lymphoma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2013;31:7005.
   Web of Science ®Google Scholar
• Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366:2008–2016.
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010; 47:107–114.
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393–4402.
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117:4519–4529.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2009;114:884.
   Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–1110.
   PubMed Web of Science ®Google Scholar
• Brown JR, O’Brien S, Kingsley CD, et al. Obinutuzumab (G) plus fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood 2015;125:2779–2785.
   PubMed Web of Science ®Google Scholar